MetaCap

Vyome (HIND) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vyome (HIND) has outperformed Quantum Biopharma (QNTM) over the past year, losing 75.9% versus a loss of 77.6%. Over five years, QNTM leads with a -98.5% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($8.4 million vs $8.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HIND-75.90%QNTM-77.60%
+107%+10%-86%
Nov 21, 20251 yearNov 20, 2026
HIND-100.00%QNTM-98.66%
+32%-37%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HIND versus QNTM key metrics
MetricHINDQNTM
Share price$1.20$1.29
Market cap$8.42M$8.29M
1-day change-17.24%-9.15%
YTD return-65.12%-82.33%
1-year return-75.90%-77.60%
5-year return-100.00%-98.51%
P/E ratio (TTM)0.25—
EPS (TTM)$4.77$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$319.71K—
Revenue growth (YoY)+24.43%—
Net income (latest FY)$-10.26M—
Gross margin68.43%—
Operating margin-3269.35%—
Net margin-3209.75%—
52-week high$5.88$12.42
52-week low$1.20$1.26
Distance from 52-week high-79.59%-89.61%
Analyst consensusstrong_buynone
Avg. price target upside+635.83%+851.16%
Average volume13.92K148.83K
Shares outstanding7.02M6.43M
Employees9—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

HIND vs QNTM FAQ

Which is bigger, Vyome or Quantum Biopharma?

Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.29M for Quantum Biopharma (QNTM).

Which stock has performed better over the past year, HIND or QNTM?

HIND returned -75.90% over the past 12 months, compared with -77.60% for QNTM (price return, excluding dividends). Past performance does not predict future results.

Are Vyome and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons